Adam Rock, M.D.

(877) 460-4673
Adam Rock, M.D.
Medical Oncologist
Clinical Expertise
  • Lung Cancer and Thoracic Oncology
  • Sarcoma
Academic Appointments
  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Thoracic Oncology
Medical Oncology & Therapeutics Research
Sarcoma, Osteosarcoma and Bone Cancer

Medical oncologist Adam Rock, M.D., grew up in a family of health care providers, a background that allowed him to see firsthand how meaningful and rewarding the relationship between provider and patient can be. Personal family encounters with cancer continue to provide meaning and motivation to his work, as he enjoys the opportunity to work at the intersection of leading-edge research and meaningful human interaction.

Joining City of Hope in 2022 after serving as a fellow there, Dr. Rock considers it the ideal setting to provide high-quality care and collaborate with regional and international experts in a range of fields. During his time as a resident at the University of Illinois at Chicago, he was recognized with the American Society of Hematology's Abstract Achievement Award, and he went on to serve as chief fellow in Oncology/Hematology at Harbor-UCLA Medical Center. As a physician-scientist, he has played a role in leading 10 previous and ongoing clinical trials as of 2019.

Location

Education & Experience

Board Certification

  • 2019 - present, California Medical License, California State Medical Board

Degrees

  • 2016, Doctor of Medicine, Chicago Medical School, Rosalind Franklin University, North Chicago, Illinois
  • 2012, Master of Science, Rosalind Franklin University, North Chicago, Illinois
  • 2011, Bachelor of Science, Michigan State University, East Lansing, Michigan

Fellowship

  • 2022, Hematology/Oncology, Harbor UCLA Medical Center, Los Angeles, California

Residency

  • 2019, Internal Medicine, University of Illinois at Chicago, Chicago, Illinois

Professional Experience

  • 2023 - Present, Director, Medical Oncology In-patient Consult Services
  • 2022 - Present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
     

Awards & Memberships

Awards

  • 2018, American Society of Hematology Abstract Achievement Award

Memberships

  • American Society of Hematology
  • American Society of Clinical Oncology
  • European Society of Medical Oncology
  • International Association for the Study of Lung Cancer
  • Connective Tissue Oncology Society

Publications

  • Rock A, Uche A, Yoon J, Agulnik M, Chow W, Millis S. Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. J Pers Med. 2023 Oct 15;13(10):1499. doi: 10.3390/jpm13101499. PMID: 37888109.
  • Chehrazi-Raffle A, Leong S, Ali S, Kim T, Melamed S, Li X, Zengin Z, Meza L, Chawla N, Govindarajan A, Castro D, Mercier B, Ebrahimi H, Dizman N, Tripathi N, Sayegh N, Rock A, Yeh J, Pal SK, Onyshchenko M. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated with First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma. Oncologist. 2023 Dec 11;28(12):1079-1084. doi: 10.1093/oncolo/oyad190. PMID: 37432304.
  • Castro DV, Prajapati SR, Feng MI, Chan EH, Lee KO, Paul T, Sehgal I, Patel J, Li X, Zengin ZB, Ebrahimi H, Govindarajan A, Meza L, Mercier BD, Chawla NS, Dizman N, Philip EJ, Hsu J, Bergerot CD, Chehrazi-Raffle A, Rock A, Liu S, Tripathi A, Dorff TB, Pal SK. Assessment of Eligibility Criteria in Renal Cell Carcinoma Trials Evaluating Systemic Therapy. BJU Int. 2024 Mar;133(3):297-304. doi: 10.1111/bju.16148. Epub 2023 Sep 1. PMID: 37548533.
  • Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia NJ, Zengin ZB, Meza L, Chawla N, Castro DV, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer RA, Boehmer L, Pal S, Chehrazi-Raffle A. Barriers to Clinical Trial Implementation Among Community Care Centers. JAMA Netw Open. 2024 Apr 1;7(4):e248739. doi: 10.1001/jamanetworkopen.2024.8739. PMID: 38683608
  • Arana I, Riew GJ, Rock A, Nambudiri VE, Modi B, Shi CR. Cutaneous toxicities associated with epidermal growth factor receptor and mesenchymal epithelial transition factor dual blockade via bispecific antibody amivantamab. J Am Acad Dermatol. 2025 Feb 6:S0190-9622(25)00197-5. doi: 10.1016/j.jaad.2025.02.007. Epub ahead of print. PMID: 39922286.
  • Gombrich W, Eustace N, Liu Y, Muddasani R, Rock A, Salgia R, Williams T, Malhotra J, Lee P, Amini A. Treatment Approaches for Oligoprogressive Non-Small Cell Lung Cancer: A Review of Ablative Radiotherapy. Cancers (Basel). 2025 Apr 5;17(7):1233. doi: 10.3390/cancers17071233. PMID: 40227825; PMCID: PMC11987937.
  • Mercier BD, Govindarajan A, Castro DV, Li X, Philip EJ, Feng MI, Prajapati SR, Chan EH, Lee KO, Sehgal I, Patel J, O'Dell A, Chehrazi-Raffle A, Ebrahimi H, Rock A, Zengin ZB, Meza LA, Dizman N, Hsu J, Liu S, Dorff TB, Pal SK, Tripathi A. Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Med. 2025 Apr;14(7):e70696. doi: 10.1002/cam4.70696. PMID: 40145383.
  • Sampath S, Rashdan S, Iyengar P, Mickel TA, Zhang S, Ahn C, Gao A, Dowell JE, Zhang Y, Westover KD, Cole SM, Amini A, Rock A, Massarelli E, Koczywas M, Gerber DE. Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025 Aug 26;87:103435. doi: 10.1016/j.eclinm.2025.103435. PMID: 41054436; PMCID: PMC12496182.
  • Hassoun R, Ben-David R, Sfakianos JP, Laliotis G, Au C, Cary C, Masterson TA, Manage K, Dutta P, Tillu N, Cumarasamy S, King J, Rich J, Rock A, Dorff T, Patel M, Sharma S, ElNaggar AC, Liu MC, Tan A, Einhorn LH, Adra N, Chehrazi-Raffle A. Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors. JCO Precis Oncol. 2025 Sep;9:e2500176. doi: 10.1200/PO-25-00176. Epub 2025 Sep 24. PMID: 40991885.
  • Rock A, Mambetsariev I, Pareek S, Fricke J, Li X, Arias-Romero J, Kareem W, Arvanitis L, Bruno DS, Gray S, Salgia R. Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition. Curr Oncol. 2025 Oct 3;32(10):554. doi: 10.3390/curroncol32100554. PMID: 41149474; PMCID: PMC12563872.
  • Garg S, Dua A, Rock A. Profound neutrophilia as the presenting sign of GCSF-secreting, ROS1-mutant squamous cell lung cancer. BMJ Case Rep. 2025 Dec 3;18(12):e267778. doi: 10.1136/bcr-2025-267778. PMID: 41338917.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Provider explain in way you understand
5.0
Provider listen carefully to you
5.0
Know important info medical history
5.0
Show respect for what you say
5.0
Spend enough time with you
4.9
Recommend this provider office
4.9
Rate provider 0-10
03/06/26
Thank you all good - Verified patient
03/06/26
All very good thank you - Verified patient
02/24/26
Dr. Rock has an EXCELLENT bedside manner. He immediately puts you at ease and makes a point to listen to what you have to say, directly respond to any concerns or questions, and conveys that he genuinely cares about you. Because he understands that waiting for test results can be extraordinarily stressful, he made a point to request that my test results be expedited and got back to me after hours - the same day - to report the results and put my mind at ease. Dr. Rock goes above and beyond for his patients and I TRULY appreciate it. - Verified patient
02/01/26
Dr. Rock listens to my concerns and answers my questions in language I understand. It's always a pleasure to see him because he is the perfect blend of compassion and knowledge. I'm very blessed to be in Dr. Rock's care. - Verified patient
01/27/26
Dr Rock is the best! We feel so blessed to have him in charge of my care.. Best ever!! - Verified patient